

Alberto Lle

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3625475/alberto-lleo-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

261
papers

12,958
citations

50
h-index

110
g-index

306
ext. papers

17,314
ext. citations

7
avg, IF

5.46
L-index

#	Paper	IF	Citations
261	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. <i>Nature Genetics</i> , 2013 , 45, 1452-8	36.3	2714
260	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019 , 51, 414-430	36.3	917
259	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1924-38	27.4	842
258	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017 , 49, 1373-1384	36.3	508
257	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. <i>Science Translational Medicine</i> , 2014 , 6, 243ra86	17.5	436
256	Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1939-49	27.4	379
255	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013 , 9, 251-61	1.2	289
254	sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , 2016 , 8, 466-72	25.6	256
253	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , 2014 , 13, 686-99	24.1	207
252	Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. <i>Nature Medicine</i> , 2004 , 10, 1065-6	50.5	187
251	Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. <i>Neurobiology of Aging</i> , 2010 , 31, 725-31	5.6	162
250	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 244-328	3.8	148
249	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016 , 12, 154-163	1.2	129
248	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 111-126	5.2	128
247	Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. <i>Journal of Neuroscience</i> , 2005 , 25, 3009-17	6.6	126
246	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. <i>Lancet Neurology</i> , 2018 , 17, 64-74	24.1	121
245	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015 , 11, 41-55	15	116

244	Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. <i>Neurology</i> , 2015 , 85, 626-33	6.5	107
243	Confluence of β synuclein, tau, and β amyloid pathologies in dementia with Lewy bodies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013 , 72, 1203-12	3.1	106
242	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet Neurology</i> , 2018 , 17, 860-869	24.1	105
241	Qualitative changes in human β secretase underlie familial Alzheimer's disease. <i>Journal of Experimental Medicine</i> , 2015 , 212, 2003-13	16.6	104
240	Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. <i>Archives of Neurology</i> , 2011 , 68, 359-64		102
239	Tau enhances β synuclein aggregation and toxicity in cellular models of synucleinopathy. <i>PLoS ONE</i> , 2011 , 6, e26609	3.7	94
238	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018 , 75, 84-95	14.5	94
237	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- β in a multicentre European memory clinic study. <i>Brain</i> , 2016 , 139, 2540-53	11.2	93
236	Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid A β 2 Levels in Cognitively Normal Elderly. <i>Sleep</i> , 2016 , 39, 2041-2048	1.1	92
235	MicroRNA Profile in Patients with Alzheimer's Disease: Analysis of miR-9-5p and miR-598 in Raw and Exosome Enriched Cerebrospinal Fluid Samples. <i>Journal of Alzheimer's Disease</i> , 2017 , 57, 483-491	4.3	90
234	Cerebrospinal fluid β amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2014 , 76, 223-30	9.4	88
233	Relationship between β Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2014 , 42, 157-67	4.3	88
232	Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. <i>Archives of Neurology</i> , 2002 , 59, 1759-63		88
231	Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , 2013 , 125, 201-13	14.3	81
230	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. <i>Neurobiology of Aging</i> , 2014 , 35, 444.e1-4	5.6	81
229	The gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	77
228	CSF sAPP β YKL-40, and neurofilament light in frontotemporal lobar degeneration. <i>Neurology</i> , 2017 , 89, 178-188	6.5	75
227	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019 , 15, 776-787	1.2	74

226	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet, The</i> , 2020 , 395, 1988-1997	4.0	74
225	YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. <i>Journal of Neuroinflammation</i> , 2017 , 14, 118	10.1	69
224	APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls. <i>Oncotarget</i> , 2015 , 6, 26663-74	3.3	67
223	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , 2017 , 38, 297-309	4.7	66
222	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. <i>Molecular and Cellular Proteomics</i> , 2019 , 18, 546-560	7.6	66
221	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in prodementia stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015 , 36, 2018-23	5.6	64
220	Synaptic phosphorylated β -synuclein in dementia with Lewy bodies. <i>Brain</i> , 2017 , 140, 3204-3214	11.2	64
219	Activity of gamma-secretase on substrates other than APP. <i>Current Topics in Medicinal Chemistry</i> , 2008 , 8, 9-16	3	63
218	Cortical microstructural changes along the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2018 , 14, 340-351	1.2	60
217	Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. <i>American Journal of Geriatric Psychiatry</i> , 2004 , 12, 146-56	6.5	60
216	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2019 , 15, 644-654	1.2	57
215	PLD3 in non-familial Alzheimer's disease. <i>Nature</i> , 2015 , 520, E3-5	50.4	53
214	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021 , 12, 3400	17.4	51
213	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019 , 15, 742-753	1.2	50
212	Low density lipoprotein receptor-related protein (LRP) interacts with presenilin 1 and is a competitive substrate of the amyloid precursor protein (APP) for gamma-secretase. <i>Journal of Biological Chemistry</i> , 2005 , 280, 27303-9	5.4	50
211	Mild cholesterol depletion reduces amyloid-beta production by impairing APP trafficking to the cell surface. <i>Journal of Neurochemistry</i> , 2009 , 110, 220-30	6	49
210	Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study. <i>Neurology</i> , 2016 , 86, 50-8	6.5	48
209	Analysis of the CHCHD10 gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. <i>Brain</i> , 2015 , 138, e400	11.2	47

208	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 684-91	5.5	47
207	Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 1815-1824	5.3	46
206	The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. <i>Alzheimer's and Dementia</i> , 2015 , 11, 195-206.e1	1.2	45
205	Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer's disease: a multicenter study in Spain. <i>Journal of Alzheimer's Disease</i> , 2014 , 39, 719-26	4.3	44
204	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 26	9	43
203	Non-Fibrillar Oligomeric Amyloid- β within Synapses. <i>Journal of Alzheimer's Disease</i> , 2016 , 53, 787-800	4.3	43
202	Current therapeutic options for Alzheimer's disease. <i>Current Genomics</i> , 2007 , 8, 550-8	2.6	42
201	CSF sAPP β YKL-40, and NFL along the ALS-FTD spectrum. <i>Neurology</i> , 2018 , 91, e1619-e1628	6.5	42
200	Notch1 competes with the amyloid precursor protein for gamma-secretase and down-regulates presenilin-1 gene expression. <i>Journal of Biological Chemistry</i> , 2003 , 278, 47370-5	5.4	40
199	MAPT H1 haplotype is associated with enhanced β synuclein deposition in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2013 , 34, 936-42	5.6	39
198	Informants' Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimer's Disease from Normal Aging. <i>Journal of Alzheimer's Disease</i> , 2015 , 48 Suppl 1, S87-98	4.3	39
197	β secretase substrates and their implications for drug development in Alzheimer's disease. <i>Current Topics in Medicinal Chemistry</i> , 2011 , 11, 1513-27	3	39
196	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017 , 13, 1251-1260	1.2	38
195	Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. <i>Nature Communications</i> , 2019 , 10, 4766	17.4	38
194	Longitudinal brain structural changes in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017 , 13, 499-509	1.2	38
193	Clinical, neuropathologic, and biochemical profile of the amyloid precursor protein I716F mutation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010 , 69, 53-9	3.1	37
192	Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. <i>Oncotarget</i> , 2018 , 9, 34691-34698	3.3	37
191	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 913-924	1.2	36

190	Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the expansion mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 162-168	5.5	36
189	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. <i>Acta Neuropathologica</i> , 2017 , 134, 475-487	14.3	34
188	Regional Overlap of Pathologies in Lewy Body Disorders. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017 , 76, 216-224	3.1	34
187	Prevalence of Sleep Disorders in Adults With Down Syndrome: A Comparative Study of Self-Reported, Actigraphic, and Polysomnographic Findings. <i>Journal of Clinical Sleep Medicine</i> , 2018 , 14, 1725-1733	3.1	34
186	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. <i>Brain</i> , 2019 , 142, 1121-1133	11.2	32
185	A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. <i>JAMA Neurology</i> , 2018 , 75, 738-745	17.2	32
184	Homocysteine and cognitive impairment. Relation with diagnosis and neuropsychological performance. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 26, 506-12	2.6	32
183	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 64	9	31
182	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. <i>Neurobiology of Aging</i> , 2014 , 35, 2657.e13-2657.e19	5.6	31
181	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015 , 6, 216	4.1	31
180	Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. <i>Oncotarget</i> , 2017 , 8, 104706-104716	3.3	31
179	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021 , 53, 294-303	36.3	31
178	Cerebral amyloid angiopathy-related atraumatic convexal subarachnoid hemorrhage: an ARIA before the tsunami. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015 , 35, 710-7	7.3	30
177	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , 2015 , 36, 2587-96	5.6	29
176	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. <i>Neurobiology of Aging</i> , 2015 , 36, 2005.e15-22	5.6	29
175	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 30	9	29
174	CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. <i>Molecular Neurobiology</i> , 2017 , 54, 6647-6654	6.2	29
173	Cerebrospinal Fluid Anti-Amyloid- β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation. <i>Journal of Alzheimer's Disease</i> , 2016 , 50, 1-7	4.3	29

172	Early-onset familial lewy body dementia with extensive tauopathy: a clinical, genetic, and neuropathological study. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009 , 68, 73-82	3.1	29
171	A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 933-938	6	29
170	Nanoscale structure of amyloid- β plaques in Alzheimer's disease. <i>Scientific Reports</i> , 2019 , 9, 5181	4.9	28
169	Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis. <i>Nature Neuroscience</i> , 2019 , 22, 1258-1268	25.5	28
168	Posttranslational nitro-glycative modifications of albumin in Alzheimer's disease: implications in cytotoxicity and amyloid- β peptide aggregation. <i>Journal of Alzheimer's Disease</i> , 2014 , 40, 643-57	4.3	28
167	Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. <i>Annals of Neurology</i> , 2017 , 82, 247-258	9.4	28
166	Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. <i>Journal of Alzheimer's Disease</i> , 2016 , 50, 539-46	4.3	28
165	New insights into the genetic etiology of Alzheimer's disease and related dementias.. <i>Nature Genetics</i> , 2022 ,	36.3	27
164	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019 , 15, 817-827	1.2	26
163	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 597-609	6	26
162	Challenges associated with biomarker-based classification systems for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 346-357	5.2	25
161	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018 , 141, 2895-2907	11.2	25
160	GBA and APOE ϵ associate with sporadic dementia with Lewy bodies in European genome wide association study. <i>Scientific Reports</i> , 2019 , 9, 7013	4.9	24
159	Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter A β production. <i>Journal of Neurochemistry</i> , 2014 , 128, 330-9	6	24
158	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021 , 12, 3417	17.4	23
157	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1478-1488	1.2	22
156	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. <i>Scientific Reports</i> , 2017 , 7, 2477	4.9	21
155	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. <i>Neurology</i> , 2021 , 96, e671-e683	6.5	21

154	Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	21
153	Mendelian genes for Parkinson's disease contribute to the sporadic forms of the disease. <i>Human Molecular Genetics</i> , 2015 , 24, 2023-34	5.6	20
152	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [F]-Flutemetamol PET Scan Result. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 409	5.3	20
151	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017 , 56, 33-40	5.6	19
150	Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum. <i>Neurobiology of Aging</i> , 2017 , 53, 192.e1-192.e4	5.6	19
149	Exome sequencing in a consanguineous family clinically diagnosed with early-onset Alzheimer's disease identifies a homozygous CTSF mutation. <i>Neurobiology of Aging</i> , 2016 , 46, 236.e1-6	5.6	19
148	Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 909-918	4.3	17
147	Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. <i>Neurology</i> , 2020 , 94, e2026-e2036	6.5	17
146	Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. <i>Scientific Reports</i> , 2019 , 9, 7803	4.9	16
145	Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis. <i>Developmental Neurobiology</i> , 2019 , 79, 716-737	3.2	16
144	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020 , 143, 3776-3792	11.2	16
143	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019 , 127, 492-501	7.9	15
142	Uncommon polymorphism in the presenilin genes in human familial Alzheimer's disease: not to be mistaken with a pathogenic mutation. <i>Neuroscience Letters</i> , 2002 , 318, 166-8	3.3	15
141	Elevated YKL-40 and low sAPP β /YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 180-186	5.5	15
140	Clinical and video-polysomnographic analysis of rapid eye movement sleep behavior disorder and other sleep disturbances in dementia with Lewy bodies. <i>Sleep</i> , 2019 , 42,	1.1	13
139	APOE ϵ genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 65	9	13
138	Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis. <i>Scientific Reports</i> , 2020 , 10, 4308	4.9	13
137	Detection of amyloid beta peptides in body fluids for the diagnosis of Alzheimer's disease: Where do we stand?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020 , 57, 99-113	9.4	13

136	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020 , 87, 139.e1-139.e7	5.6	13
135	HTT gene intermediate alleles in neurodegeneration: evidence for association with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019 , 76, 215.e9-215.e14	5.6	13
134	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. <i>Neurobiology of Aging</i> , 2018 , 66, 181.e3-181.e10	5.6	12
133	Acetylcholinesterase modulates presenilin-1 levels and β secretase activity. <i>Journal of Alzheimer's Disease</i> , 2014 , 41, 911-24	4.3	12
132	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 1489-1496	4.3	12
131	Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 ,	5.5	12
130	Active bilingualism delays the onset of mild cognitive impairment. <i>Neuropsychologia</i> , 2020 , 146, 107528	3.2	11
129	Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016 , 171B, 175-80	3.5	11
128	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. <i>Neurobiology of Aging</i> , 2018 , 69, 293.e9-293.e11	5.6	11
127	Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. <i>Clinica Chimica Acta</i> , 2019 , 490, 98-101	6.2	11
126	Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 , 17, 618-628	1.2	11
125	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021 , 12, 4304	17.4	11
124	Association of Apolipoprotein E e4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2021 , 78, 937-947	17.2	11
123	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020 , 74, 213-225	4.3	10
122	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 73, 1585-1595	4.3	10
121	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017 , 49, 214.e13-214.e15	5.6	10
120	Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 123	9	10
119	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020 , 10, 403	8.6	10

118	Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuum. <i>Neurology</i> , 2020 , 95, e2565-e2576	6.5	10
117	Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome. <i>Molecular Neurodegeneration</i> , 2020 , 15, 46	19	10
116	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 1206-1214	5.5	10
115	APP-derived peptides reflect neurodegeneration in frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 2518-2530	5.3	10
114	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019 , 75, 223.e1-223.e10	5.6	10
113	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1329-1341	1.2	10
112	Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, 505-513	4.3	9
111	Cerebral perfusion and haemodynamics measured by SPET in symptom-free patients with transient ischaemic attack: clinical implications. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001 , 28, 1828-35	8.8	9
110	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , 2022 ,	17.2	9
109	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <i>International Journal of Geriatric Psychiatry</i> , 2021 , 36, 324-333	3.9	9
108	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. <i>Lancet Neurology</i> , 2021 , 20, 605-614	24.1	9
107	Neuropsychological deficits in patients with cognitive complaints after COVID-19.. <i>Brain and Behavior</i> , 2022 , e2508	3.4	8
106	Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study. <i>Alzheimer's and Dementia</i> , 2021 , 17, 605-617	1.2	8
105	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018 , 66, 639-652	4.3	8
104	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 543-555	4.3	7
103	Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?. <i>Clinica Chimica Acta</i> , 2019 , 491, 81-84	6.2	7
102	Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018 , 64, 58-67	5.6	7
101	Assessing the role of TUBA4A gene in frontotemporal degeneration. <i>Neurobiology of Aging</i> , 2016 , 38, 215.e13-215.e14	5.6	7

100	Presenilin-1 influences processing of the acetylcholinesterase membrane anchor PRiMA. <i>Neurobiology of Aging</i> , 2014 , 35, 1526-36	5.6	7
99	Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion. <i>Alzheimer Disease and Associated Disorders</i> , 2015 , 29, 353-6	2.5	7
98	Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases. <i>Frontiers of Neurology and Neuroscience</i> , 2016 , 39, 117-23	1.1	7
97	Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2019 , 124, 428-438	7.5	7
96	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of A β species. <i>NeuroImage: Clinical</i> , 2018 , 20, 603-610	5.3	7
95	Diagnostic value of plasma neurofilament light: A multicentre validation study		6
94	State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	6
93	Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016 , 11, 66	19	6
92	The pitfalls of biomarker-based classification schemes. <i>Alzheimer's and Dementia</i> , 2017 , 13, 1072-1074	1.2	5
91	Annexin A5 prevents amyloid- β induced toxicity in choroid plexus: implication for Alzheimer's disease. <i>Scientific Reports</i> , 2020 , 10, 9391	4.9	4
90	Distinct Clinical Features and Outcomes in Motor Neuron Disease Associated with Behavioural Variant Frontotemporal Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018 , 45, 220-231	2.6	4
89	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 1353-1368	4.3	4
88	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1452-1464	1.2	4
87	AMYQ: An index to standardize quantitative amyloid load across PET tracers. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1499-1508	1.2	4
86	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1628-1640	1.2	4
85	Kidins220 Correlates with Tau in Alzheimer's Disease Brain and Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 1327-1333	4.3	4
84	O5-02-04: DOWN ALZHEIMER BARCELONA NEUROIMAGING INITIATIVE (DABNI): A PROSPECTIVE LONGITUDINAL BIOMARKER COHORT TO STUDY ALZHEIMER'S DISEASE IN DOWN SYNDROME 2016 , 12, P380-P381		4
83	Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 99-111	5.2	4

82	Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid- β positivity. <i>Cortex</i> , 2019 , 121, 117-124	3.8	3
81	Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	3
80	Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1535-1538	5	3
79	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021 , 17,	1.2	3
78	Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12052	5.2	3
77	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. <i>JAMA Network Open</i> , 2021 , 4, e211290	10.4	3
76	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 712545	5.3	3
75	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. <i>Neurobiology of Aging</i> , 2021 , 99, 99.e15-99.e22	5.6	3
74	Multilingualism in semantic dementia: language-dependent lexical retrieval from degraded conceptual representations. <i>Aphasiology</i> , 2021 , 35, 240-266	1.6	3
73	Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. <i>Annals of Neurology</i> , 2021 , 90, 407-416	9.4	3
72	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview.. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	3
71	P4-267: CORE ALZHEIMER'S DISEASE CSF BIOMARKERS IN DOWN SYNDROME 2014 , 10, P882-P882		2
70	[O31003]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY 2017 , 13, P924		2
69	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 ,	5.9	2
68	Agreement between 18F-Florbetapir PET imaging and cerebrospinal fluid A β -42, A β -40, tTau and pTau measured on the LUMIPULSE G fully automated platform		2
67	CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2021 , 103, 158.e1-158.e5	5.6	2
66	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2021 , 79, 163-175	4.3	2
65	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021 , 9,	4.6	2

64	Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. <i>JAMA Network Open</i> , 2022 , 5, e2212910	10.4	2
63	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 1065-1074	4.3	1
62	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020 , 16, e036954	1.2	1
61	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e047209	1.2	1
60	The Added Value of Tau-PET in the Assessment of Progressive Supranuclear Palsy. <i>Clinical Nuclear Medicine</i> , 2020 , 45, e239-e240	1.7	1
59	Alzheimer's disease: An ignored condition. <i>Medicina Clínica (English Edition)</i> , 2018 , 150, 432-433	0.3	1
58	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study 2015 , 11, P297-P297		1
57	Effect of REST on brain metabolism in the Alzheimer disease continuum. <i>Annals of Neurology</i> , 2015 , 78, 661-2	9.4	1
56	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions 2015 , 11, P384-P384		1
55	Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases. <i>Cells</i> , 2020 , 9,	7.9	1
54	Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2021 , 81, 629-640	4.3	1
53	VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 119	9	1
52	P1-277: CORRELATION BETWEEN INNOTEST [®] AND THE FULLY AUTOMATED LUMIPULSE [®] G PLATFORM FOR THE ANALYSIS OF β AMYLOID 1-42 AND TOTAL TAU 2018 , 14, P388-P389		1
51	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.. <i>Molecular Neurodegeneration</i> , 2022 , 17, 27	19	1
50	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration.. <i>Molecular Neurodegeneration</i> , 2022 , 17, 29	19	1
49	Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. <i>Translational Neurodegeneration</i> , 2021 , 10, 50	10.3	1
48	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2021 , 17,	1.2	1
47	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration.. <i>JAMA Network Open</i> , 2022 , 5, e229588	10.4	1

46	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. <i>PLoS ONE</i> , 2022 , 17, e0267298	3.7	1
45	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies.. <i>Frontiers in Neurology</i> , 2021 , 12, 750543	4.1	0
44	The A β -42/A β -40 ratio in CSF is more strongly associated to tau markers and clinical progression than A β -42 alone.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 20	9	0
43	Cortical microstructure in primary progressive aphasia: a multicenter study.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 27	9	0
42	Evaluation of biochemical and hematological parameters in adults with Down syndrome. <i>Scientific Reports</i> , 2020 , 10, 13755	4.9	0
41	Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2021 , 10, 37	10.3	0
40	Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 160	9	0
39	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles.. <i>Journal of Neural Transmission</i> , 2022 , 129, 231	4.3	0
38	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 840651	5.3	0
37	Exome sequencing identifies rare damaging variants in the ATB8B4 and ABCA1 genes as novel risk factors for Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e055982	1.2	0
36	[O10602]: BIPHASIC MODEL IN PRECLINICAL ALZHEIMER'S DISEASE: AV45 PET, CSF TAU AND CORTICAL THICKNESS 2017 , 13, P201-P202		
35	AmyQ: An index to accurately measure cerebral amyloid load. <i>Alzheimer's and Dementia</i> , 2020 , 16, e039735		
34	Oligodendroglial alterations in FTD caused by C9orf72 expansion. <i>Alzheimer's and Dementia</i> , 2020 , 16, e040196	1.2	
33	Cerebrospinal fluid neuroinflammatory biomarkers along the Alzheimer disease continuum in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041255	1.2	
32	Characteristics and prognosis of patients with mild cognitive impairment by cerebrospinal fluid biomarker profiles. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041500	1.2	
31	Quantifying the synaptic vesicle-associated protein, VAMP2, to verify changes in cerebrospinal fluid in preclinical stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042717	1.2	
30	Transcriptome characterization of the motor cortex suggests microglial-related key events due to TDP-43 aberrant inclusions. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042953	1.2	
29	¹ H-MRS signature in Alzheimer disease in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020 , 16, e0433461.2		

28	Domiciliary Alzheimer visiting in Down syndrome pilot project: Preliminary results. <i>Alzheimer's and Dementia</i> , 2020 , 16, e043491	1.2
27	Longitudinal plasma levels of neurofilament light in Down syndrome: A multicenter study. <i>Alzheimer's and Dementia</i> , 2020 , 16, e044772	1.2
26	Which pre-analytical confounder matters the most in the comparison of two cohorts? Tubes and storage fill volume put to the test. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045060	1.2
25	VAMP2 is a cerebrospinal fluid marker of selective hippocampal synapse loss and episodic memory performance in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045268	1.2
24	Blood-based detection of early-stage Alzheimer using multiomics and machine learning. <i>Alzheimer's and Dementia</i> , 2020 , 16, e047334	1.2
23	S4-01-01: Cross-Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau 2016 , 12, P321-P321	
22	[P1866]: WEIGHT LOSS MIGHT BE A NON-COGNITIVE SIGN OF PRECLINICAL ALZHEIMER'S DISEASE 2017 , 13, P399-P400	
21	[P3074]: STRUCTURAL CORRELATES OF ALZHEIMER'S DISEASE AND AGING IN DOWN SYNDROME: AN MRI STUDY 2017 , 13, P1048-P1048	
20	[P1038]: THE SAPP/APPYKL-40 RATIO IN CEREBROSPINAL FLUID AS A DIAGNOSTIC MARKER IN FRONTOTEMPORAL LOBAR DEGENERATION: A PATHOLOGICAL STUDY 2017 , 13, P335-P336	
19	[P1089]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF A β OR AMYLOID-PET) IN THE EMIF-AD BIOMARKER DISCOVERY COHORT 2017 , 13, P361-P362	
18	[P2059]: NETWORK ANALYSIS OF THE CSF PROTEOME IDENTIFIES SYNAPTIC PROTEINS OF HIPPOCAMPAL ORIGIN AS PUTATIVE BIOMARKERS FOR AD-RELATED SYNAPSE LOSS 2017 , 13, P712-P712	
17	P1-121: Comparison of different β amyloid isoforms in CSF to detect amyloid pathology in cognitively normal subjects and patients with dementia 2015 , 11, P387-P387	
16	P3-230: CSF β AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD 2014 , 10, P715-P715	
15	IC-P-217: CSF β AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD 2014 , 10, P117-P117	
14	P4-122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer's Disease and Its Influence on Cognitive Decline 2016 , 12, P1059-P1061	
13	P2-424: Obesity is Associated With Increased CSF Phospho-TAU Levels and Cognitive Decline in Healthy Elderly 2016 , 12, P807-P807	
12	O5-05-02: EVALUATION OF SYNAPTIC PROTEINS AS CEREBROSPINAL FLUID STAGE BIOMARKERS FOR ALZHEIMER'S DISEASE 2016 , 12, P388-P388	
11	P4-525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE 2019 , 15, P1515-P1516	

10 IC-P-148: THE CORTICAL MICROSTRUCTURAL SIGNATURE OF ALZHEIMER'S DISEASE **2019**, 15, P119-P120

9 O2-09-01: THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME **2019**, 15, P558-P560

8 P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT **2018**, 14, P1161-P1161

7 P4-076: CEREBROSPINAL FLUID CORE BIOMARKERS ALLOW AN ACCURATE DIAGNOSIS OF ALZHEIMER'S DISEASE IN DOWN SYNDROME **2018**, 14, P1463-P1464

6 F1-02-04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY **2018**, 14, P204-P204

5 P2-262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM **2018**, 14, P777-P777

4 P3-394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS **2018**, 14, P1248-P1249

3 O5-04-01: A RARE GENETIC VARIANT IN THE PLCG2 GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE **2018**, 14, P1648-P1649

2 P1-293: IDENTIFICATION OF EXOSOMAL MICRORNAS AS POTENTIAL DIAGNOSTIC BIOMARKERS FOR FRONTOTEMPORAL DEMENTIA **2018**, 14, P398-P399

1 Transcriptome-wide characterization of the frontal cortex in FTLD.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 3, e049569

1.2